LEVODOPA-CARBIDOPA DIN 02182831
Health Canada record
| Active ingredient(s) | CARBIDOPA 10 MG; LEVODOPA 100 MG |
|---|---|
| Dosage form | Tablet |
| Route | Oral |
| Schedule | PRESCRIPTION |
| Class | Human |
| ATC | N04BA02 LEVODOPA AND DECARBOXYLASE INHIBITOR |
| Original market date | 31-Dec-1996 |
| Current status date | 30-May-2024 |
| Source | Health Canada DPD |
Establishment licence of the holder
Apotex Inc — licence 100375, currently licensed, last inspection rating C (2026-04-21).
No Canadian shortage report is currently matched to this DIN.
Other Canadian products containing CARBIDOPA
| DIN | Product | Company | Form | Strength | Status |
|---|---|---|---|---|---|
| 02195941 | APO-LEVOCARB | APOTEX INC | Tablet | CARBIDOPA 25 MG; LEVODOPA 100 MG | Marketed |
| 02195933 | APO-LEVOCARB | APOTEX INC | Tablet | CARBIDOPA 10 MG; LEVODOPA 100 MG | Marketed |
| 02195968 | APO-LEVOCARB | APOTEX INC | Tablet | CARBIDOPA 25 MG; LEVODOPA 250 MG | Marketed |
| 02546418 | JAMP LEVOCARB | JAMP PHARMA CORPORATION | Tablet | CARBIDOPA 25 MG; LEVODOPA 100 MG | Marketed |
| 02546426 | JAMP LEVOCARB | JAMP PHARMA CORPORATION | Tablet | CARBIDOPA 25 MG; LEVODOPA 250 MG | Marketed |
| 02546396 | JAMP LEVOCARB | JAMP PHARMA CORPORATION | Tablet | CARBIDOPA 10 MG; LEVODOPA 100 MG | Marketed |
| 02182823 | LEVODOPA-CARBIDOPA | APOTEX INC | Tablet | CARBIDOPA 25 MG; LEVODOPA 100 MG | Approved |
| 02182858 | LEVODOPA-CARBIDOPA | APOTEX INC | Tablet | CARBIDOPA 25 MG; LEVODOPA 250 MG | Approved |
| 02549735 | PMS-LEVODOPA-CARBIDOPA | PHARMASCIENCE INC | Tablet | CARBIDOPA 25 MG; LEVODOPA 250 MG | Marketed |
| 02549727 | PMS-LEVODOPA-CARBIDOPA | PHARMASCIENCE INC | Tablet | CARBIDOPA 25 MG; LEVODOPA 100 MG | Marketed |
| 02549719 | PMS-LEVODOPA-CARBIDOPA | PHARMASCIENCE INC | Tablet | CARBIDOPA 10 MG; LEVODOPA 100 MG | Marketed |
| 02568799 | PRO-LEVOCARB | PRO DOC LIMITEE | Tablet | CARBIDOPA 10 MG; LEVODOPA 100 MG | Approved |
| 02568810 | PRO-LEVOCARB | PRO DOC LIMITEE | Tablet | CARBIDOPA 25 MG; LEVODOPA 250 MG | Approved |
| 02568802 | PRO-LEVOCARB | PRO DOC LIMITEE | Tablet | CARBIDOPA 25 MG; LEVODOPA 100 MG | Approved |
| 02244496 | TEVA-LEVOCARBIDOPA | TEVA CANADA LIMITED | Tablet | CARBIDOPA 25 MG; LEVODOPA 250 MG | Marketed |
| 02244495 | TEVA-LEVOCARBIDOPA | TEVA CANADA LIMITED | Tablet | CARBIDOPA 25 MG; LEVODOPA 100 MG | Marketed |
| 02247606 | DOM-LEVO-CARBIDOPA | DOMINION PHARMACAL | Tablet | CARBIDOPA 25 MG; LEVODOPA 100 MG | Cancelled Post Market |
| 02223287 | PRO-LECARB-100/10 - TAB | PRO DOC LIMITEE | Tablet | CARBIDOPA 10 MG; LEVODOPA 100 MG | Cancelled Post Market |
| 02223295 | PRO-LECARB-100/25 - TAB | PRO DOC LIMITEE | Tablet | CARBIDOPA 25 MG; LEVODOPA 100 MG | Cancelled Post Market |
| 00328219 | SINEMET | ORGANON CANADA INC. | Tablet | CARBIDOPA 25 MG; LEVODOPA 250 MG | Cancelled Post Market |
| 00513997 | SINEMET | ORGANON CANADA INC. | Tablet | CARBIDOPA 25 MG; LEVODOPA 100 MG | Cancelled Post Market |
| 02244494 | TEVA-LEVOCARBIDOPA | TEVA CANADA LIMITED | Tablet | CARBIDOPA 10 MG; LEVODOPA 100 MG | Dormant |
Notices of Compliance
| NOC | Date | Submission | Reason |
|---|---|---|---|
| 33353 | 2024-05-30 | New Drug Submission (NDS) | Administrative: Change in Product Ownership Product Monograph Reformatted to the Master Template Update to the Product Monograph with most recent safety updates Update to Labels Change Product Name |
| 4298 | 1996-01-26 | Supplement to a New Drug Submission (SNDS) | PRODUCT NAME CHANGE |
| 4937 | 1995-09-05 | New Drug Submission (NDS) |
International API supply for CARBIDOPA
15 active FDA Drug Master Files.
Request a quote for LEVODOPA-CARBIDOPA